Clobetasol
| Evidence Level: L3 | Predicted Indications: 1 |
Table of Contents
- Clobetasol
- Clobetasol: From Topical Corticosteroid-Responsive Skin Conditions to Primary Cutaneous T-Cell Lymphoma
Clobetasol: From Topical Corticosteroid-Responsive Skin Conditions to Primary Cutaneous T-Cell Lymphoma
One-Sentence Summary
Clobetasol is a super-potent topical corticosteroid, here represented by a clobetasol/neomycin/nystatin ointment product marketed in the UK. The TxGNN model predicts it may be effective for primary cutaneous T-cell lymphoma (mainly early-stage mycosis fungoides), with no registered clinical trials but 14 publications, including several cohort studies and clinical series, currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in the data compiled for this report |
| Predicted New Indication | Primary cutaneous T-cell lymphoma |
| TxGNN Prediction Score | 99.51% |
| Evidence Level | L3 |
| UK Market Status | Marketed |
| Number of Marketing Authorisations | 1 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the compiled data. Clobetasol propionate is a super-potent topical glucocorticoid. Glucocorticoid receptor activation is known to induce apoptosis in malignant T cells and to suppress local inflammatory and cytokine signalling in the skin.
This is the rationale for using topical corticosteroids in early-stage (patch/plaque) mycosis fungoides, the most common form of primary cutaneous T-cell lymphoma. The high TxGNN score is consistent with this known pharmacology.
The effect is expected to be limited to skin-directed treatment of early-stage disease. It is not expected to help in advanced or systemic disease such as Sézary syndrome or angioimmunoblastic T-cell lymphoma.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 14686970 | 2003 | Clinical series | Dermatol Ther | About 200 patients with patch-stage mycosis fungoides treated with mainly high-potency topical corticosteroids; response rate over 90% with minor side effects; topical clobetasol is first-line for early-stage disease at UCSF |
| 32603400 | 2020 | Retrospective cohort | Cutis | Evaluated cutaneous adverse effects of clobetasol propionate 0.05% cream in early-stage mycosis fungoides; superpotent steroids described as effective with minor side effects |
| 39741016 | 2025 | Cohort | An Bras Dermatol | Compared clobetasol propionate with bexarotene in early-stage mycosis fungoides; few prior comparative studies of topical treatments |
| 25027222 | 2014 | Case report | Ned Tijdschr Geneeskd | Child with hypopigmented mycosis fungoides successfully treated with clobetasol 0.05% ointment four days a week |
| 8987063 | 1996 | Case series | Pediatr Dermatol | Weekly pulse superpotent topical corticosteroid therapy in three children with lymphomatoid papulosis |
| 23773745 | 2013 | Case report | Ann Dermatol Venereol | Case and literature review of papular mycosis fungoides, a newly described early form |
| 36846176 | 2023 | Case report/Review | Clin Case Rep | Mycosis fungoides with psoriasiform plaques, initially misdiagnosed as psoriasis and not responding to topical steroids |
| 28031140 | 2016 | Case report | Skinmed | Angioimmunoblastic T-cell lymphoma presenting in skin; worsened on methotrexate and topical clobetasol, indicating poor prognosis (indirect evidence) |
UK Market Information
| Marketing Authorisation Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 1304000G0AACBCB | Clobetasol/Neomycin/Nystatin Ointment | Not stated | Not stated |
Dosage form and approved indication details were not available in the data compiled for this report. The authorisation number shown is not in standard MHRA PL format, so please verify it against the MHRA register.
Safety Considerations
Drug Interactions: 175 potential interactions were recorded, but none has a severity grading. Examples include other corticosteroids (hydrocortisone, prednisolone, prednisone, triamcinolone), proton pump inhibitors (omeprazole, pantoprazole, lansoprazole), doxycycline, metronidazole, vancomycin, clotrimazole, morphine, calcitriol and vitamin A. Clinical significance should be checked in the BNF.
Please refer to the SmPC and BNF for warnings and contraindications. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The pharmacological rationale is well established, and observational data (a clinical series of about 200 patients and two cohort studies) support clobetasol in early-stage mycosis fungoides. However, there are no registered trials or RCTs, and the evidence is limited to skin-directed treatment of early-stage disease.
To proceed, the following is needed:
- Prospective or controlled trial data in early-stage mycosis fungoides
- Confirmation of the UK approved indication, dosage form and SmPC safety information (warnings and contraindications) for the specific product
- Clarification of whether the evidence for single-agent clobetasol applies to the clobetasol/neomycin/nystatin combination
- Mechanism of action data from DrugBank
- A monitoring plan for local skin adverse effects (e.g. atrophy) and systemic absorption with prolonged use
- Restriction to early-stage disease, with specialist dermatology or haemato-oncology oversight
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.